Last Friday saw a notable increase in the share price of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), with the stock closing at $8.92 after rising 90.19%. The spike came after a significant regulatory win.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
FDA Gives VOQUEZNA Key Exclusivity
PHAT’s December 2024 Citizen Petition was accepted by the U.S. Food and Drug Administration (FDA). By acknowledging a complete ten years of New Chemical Entity (NCE) exclusivity for Phathom Pharmaceuticals’ gastrointestinal medication, VOQUEZNA (vonoprazan), through May 3, 2032, the agency reaffirmed its intention to update the Orange Book.
Novel Treatment for GERD and Erosive Esophagitis
VOQUEZNA, a first-in-class potassium-competitive acid blocker (PCAB), is the only FDA-approved treatment of its kind for treating all forms of Erosive Esophagitis (EE), also known as Erosive GERD, and for treating heartburn in adult patients with Non-Erosive Gastroesophageal Reflux Disease (GERD). Its rapid and sustained acid suppression activity sets it apart from more conventional therapies like proton pump inhibitors (PPIs).
Raising Awareness Through Collaboration With Celebrities
As part of its “GERD IS NO JOKE” public awareness campaign earlier this year, Phathom Pharmaceuticals teamed up with comedian and actor Kenan Thompson, who is well-known for his time on Saturday Night Live. Thompson, who has experienced non-erosive GERD firsthand, talked about how VOQUEZNA helped him deal with his lingering symptoms.
Over 65 million Americans suffer with GERD, and his activism seeks to raise awareness of the condition among the general public and to stimulate discussions about better treatment choices with medical experts.
Actual Data and Ongoing Outreach
At the most recent Digestive Disease Week (DDW) conference in San Diego, Phathom Pharmaceuticals also gave a presentation of positive real-world data for VOQUEZNA. Despite using both prescription and over-the-counter drugs, many GERD patients still have severe symptoms.
A possible substitute is provided by VOQUEZNA’s distinct manner of action. Phathom Pharmaceuticals (PHAT) is striving to change the treatment landscape for illnesses connected to acid reflux and make sure patients are aware of cutting-edge, practical remedies through its continuous research and outreach.
